Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PBLS
Strong SellSinkerParabilis Medicines, Inc. · Healthcare · United States · $4.8B · Avg Vol: $14M/d
2
StockRankGet insider-trade alerts
Q
19
V
23
M
21
P/E (TTM)
—
ROE
—
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment.
FINANCIAL SUMMARY (USD)
| Year | 2024 | 2025 | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | — | 1.0M | 3.3M | — |
| EPS | -2.01 | -1.81 | -1.87 | -2.58 | -2.19 | — |
| Shares | 118.1M | 118.1M | 122.0M | — | — | — |
| Debt | 66.2M | 58.7M | 47.5M | — | — | — |
| Equity | 56.4M | -16.5M | — | — | — | — |
| Op CF | -103.6M | -123.7M | -111.3M | — | — | — |
| Inv CF | 30.2M | 39.8M | — | — | — | — |
| Fin CF | 78.1M | 64.4M | — | — | — | — |
Loading 1Y...
PRICE (1Y)+12.5%
SMA 50SMA 200
Close
$36.32
RSI (14)
30.7
SCORE BREAKDOWN
Quality
19
ROIC
-600.8%0.8
ROE
—N/A
GP/Assets
-16.0%5.4
Op. Margin
-34382.4%1.2
FCF/Assets
-153.5%1.0
Piotroski
29.5
Int. Cover
-50.0x5.8
D/E Ratio
0.05x72.3
Current Ratio
17.91x95.0
Value
23
P/E (TTM)
—N/A
EV/EBITDA
-23.2x25.0
P/FCF
—N/A
P/B
4.8x30.3
P/S
33737.9x0.2
Div Yield
—N/A
Momentum
21
52W High %
—N/A
RS 6M
—N/A
SMA 50/200
—N/A
EPS Rev 4W
-15.1%6.3
EPS Rev 12W
—N/A
EPS Improve
-17%15.5
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$4.8B
P/E (Forward)
-18.5x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PBLS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PBLS | Parabilis Medicines, Inc.(you) | $4.8B | 2 | Strong Sell |
| CELC | Celcuity Inc. | $4.3B | 10 | Strong Sell |
| DYN | Dyne Therapeutics, Inc. | $4.7B | 12 | Strong Sell |
| VRDN | Viridian Therapeutics, Inc. | $2.6B | 4 | Strong Sell |
| COGT | Cogent Biosciences, Inc. | $6.0B | 12 | Strong Sell |
| RCUS | Arcus Biosciences, Inc. | $3.7B | 12 | Strong Sell |
| VERA | Vera Therapeutics, Inc. | $2.5B | 5 | Strong Sell |
| ALMS | Alumis Inc. | $2.9B | 9 | Strong Sell |
| GPCR | Structure Therapeutics Inc. | $3.4B | 13 | Strong Sell |
| ERAS | Erasca, Inc. | $6.3B | 15 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%